Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03850678 · ClinicalTrials.gov registry record · NA
Restoration of Spectral Resolution With Hearing-aid Amplification
A NA study, sponsored by University of Nebraska Lincoln.
- Completed
- Registry status
- NA
- Development phase
- 209
- Enrollment target
NCT03850678: Completed NA study, sponsored by University of Nebraska Lincoln.
NCT03850678 is a NA study that has completed, run by University of Nebraska Lincoln. The registered enrollment target is 209 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03850678, a NA study, has completed, sponsored by University of Nebraska Lincoln.
- COMPLETED
- Registry status
- NA
- Development phase
- 209 participants
- Enrollment target
Study Summary
The objective of this study protocol is to determine the efficacy of using aided measures of spectral resolution to set the dynamic range of hearing with hearing-aid amplification. Measures of spectral resolution will be obtained, as will measures of speech recognition.
Primary Outcome
Measure of spectral resolution (Q10) obtained from the fast psychophysical tuning curve test. For this study, Q10 was computed as the target frequency divided by the bandwidth of the tuning curve (10 dB above the threshold at the tip of the tuning curve test). Higher numbers on this scale indicate sharper (better) tuning. The lower limit for this scale is 0 and there is no upper limit.
Interventions
- DEVICE Hearing Aid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2023-11-30 |
| Phase | NA |
What the finished NCT03850678 record still lists
NCT03850678 is an interventional study that assigns participants to a tested intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Hearing Aid is the first listed.
NCT03850678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03850678 about?
NCT03850678 is a clinical study titled "Restoration of Spectral Resolution With Hearing-aid Amplification". The objective of this study protocol is to determine the efficacy of using aided measures of spectral resolution to set the dynamic range of hearing with hearing-aid amplification. Measures of spectral resolution will be obtained, as will measures of speech recognition.
What is the current status of trial NCT03850678?
This trial is currently completed. It is a NA study. The enrollment target is 209 participants. The study started on 2019-04-02. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT03850678?
The interventions under investigation include: Hearing Aid (DEVICE).
Who is sponsoring clinical trial NCT03850678?
This trial is sponsored by University of Nebraska Lincoln, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03850678's enrollment target sits among peer trials
209 496th of 2000 higher than 1,505 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI